Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Redfern

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
BJU International|March 12, 2024
The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancerDickon Hayne, Katherine Ong, Nicole Swarbrick, et al.
Cancer Research|January 17, 2020
Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer MetastasisBedrich L Eckhardt, Yuan Cao, Andrew D Redfern, et al.
Chemical Science|October 8, 2019
Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymersJessica A Kretzmann, Cameron W Evans, Colette Moses, et al.
JAMA Oncology|January 13, 2018
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical TrialLuca Gianni, Mauro Mansutti, Antonio Anton, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2013
RNA-induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulatorsAndrew D Redfern, Shane M Colley, Dianne J Beveridge, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 29, 2025
Aboriginal and Torres Strait Islander females and survival from breast cancerAlice R T Bergin, Luc Te Marvelde, Roger L Milne, et al.
Cell Death & Disease|July 27, 2025
Inhibition of the Caveolin-1 pathway promotes apoptosis and overcomes pan-tyrosine kinase inhibitor resistance in hepatocellular carcinomaTasnuva D Kabir, Samuel Beck, Lisa M Stuart, et al.
Molecular Cell|June 10, 2006
SLIRP, a small SRA binding protein, is a nuclear receptor corepressorEsme C Hatchell, Shane M Colley, Dianne J Beveridge, et al.
European Urology|February 3, 2026
Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)Dickon Hayne, Alison Y Zhang, Hayley Thomas, et al.
The Lancet. Oncology|December 3, 2023
Overall survival with [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
BJU International|March 12, 2024
The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancerDickon Hayne, Katherine Ong, Nicole Swarbrick, et al.
Cancer Research|January 17, 2020
Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer MetastasisBedrich L Eckhardt, Yuan Cao, Andrew D Redfern, et al.
Chemical Science|October 8, 2019
Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymersJessica A Kretzmann, Cameron W Evans, Colette Moses, et al.
JAMA Oncology|January 13, 2018
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical TrialLuca Gianni, Mauro Mansutti, Antonio Anton, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2013
RNA-induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulatorsAndrew D Redfern, Shane M Colley, Dianne J Beveridge, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 29, 2025
Aboriginal and Torres Strait Islander females and survival from breast cancerAlice R T Bergin, Luc Te Marvelde, Roger L Milne, et al.
Cell Death & Disease|July 27, 2025
Inhibition of the Caveolin-1 pathway promotes apoptosis and overcomes pan-tyrosine kinase inhibitor resistance in hepatocellular carcinomaTasnuva D Kabir, Samuel Beck, Lisa M Stuart, et al.
Molecular Cell|June 10, 2006
SLIRP, a small SRA binding protein, is a nuclear receptor corepressorEsme C Hatchell, Shane M Colley, Dianne J Beveridge, et al.
European Urology|February 3, 2026
Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)Dickon Hayne, Alison Y Zhang, Hayley Thomas, et al.
The Lancet. Oncology|December 3, 2023
Overall survival with [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Pageof 5